Phase I Study of LOR-253 in Patients with Advanced or Metastatic Solid Tumors

Full Title
Open-Label Phase I Study of LOR-253 HCL in Patients with Advanced or Metastatic Solid Tumors

The purpose of this study is to find the highest dose of an investigational drug called LOR-253 that can be given safely in patients with advanced solid tumors that are not responding to standard therapies. LOR-253 works by inhibiting the concentration of zinc in cancer cells, leading to disruption of certain proteins and eventually to cancer cell death.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have a confirmed diagnosis of an advanced solid tumor that is not responding to standard therapy or for which no standard therapy exists.
  • At least 3 weeks must have passed since completion of prior therapies and entry into the study, and patients must have recovered from any serious side effects.
  • Patients with iron or copper overload syndromes (such as hemochromatosis or Wilson’s disease) may not participate.
  • Patients must be age 18 or older.

For more information about this study and to inquire about eligibility, please contact Dr. Andrea Cercek at 646-888-4189.